<DOC>
	<DOC>NCT02085473</DOC>
	<brief_summary>The aim of this study is to evaluate the pharmacokinetics and tolerability of tralokinumab when delivered at different flow rates to healthy volunteers.</brief_summary>
	<brief_title>A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Key Healthy males and females ages 1965 years Body mass index of 19.030.0 kg/m2 No clinically significant abnormality Vital signs, electrocardiogram (ECG), and laboratory parameters within normal range Negative alcohol and drug screens Females of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception Nonsterilized males who are sexually active with a female partner of childbearing potential must use highly effective contraception Key Concurrent enrollment in another clinical study where the subject is receiving an investigational product Receipt of any marketed or investigational biologic agent within 4 months or 5 halflives prior to screening, whichever is longer Receipt of any investigational nonbiologic agent within 3 months or 5 halflives prior to screening, whichever is longer Current use of regular painmodifying, antidepressant, anxiolytic, or hypnotic medication History of thrombocytopenia or bleeding disorder or use of anticoagulants History of any immunodeficiency disorder or use of immunosuppressive medication. History of a clinically significant infection History of cancer Hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>